Livagen

• Chromatin decondensation effects that may decondense chromatin, supporting activation of genes that can become silenced with age related chromatin condensation.
• Immune system activation signaling that may influence lymphocytes and enhance immune responses, with research interest spanning systems such as the heart, gastrointestinal tract, and central nervous system.
• Enkephalin degrading enzyme inhibition that may inhibit enkephalin degrading enzymes in human serum, potentially influencing pain perception and stress response signaling.
• Immune support signaling that may enhance immune cell activity and support overall defense related endpoints.
• Neurological benefit signaling through modulation of enkephalin levels, with research interest in pain management and stress resilience.

• Anti aging potential signals tied to gene activation and chromatin decondensation, with emphasis on supporting a more youthful cellular profile.
• Immune support focused on improved immune cell activity and defense mechanism endpoints.
• Neurological support interest tied to pain and stress resilience signaling via enkephalin related modulation.

Livagen is described as well tolerated in research settings with minimal side effects reported. However, comprehensive safety data are described as limited, and additional research is needed to more fully characterize its safety profile.